Exhibit 99.1
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities
– Advancing Plans to Initiate Pivotal Study forAd-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer –
- Company to Host Conference Call Today at 4:30 p.m. ET -
BOSTON, May 1, 2017–ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced its financial results for the first quarter ended March 31, 2017, and provided an update on the company’s recent activities.
“ZIOPHARM is making significant advances, including progress towards finalizing a registration path forAd-RTS-hIL-12 + veledimex for recurrent glioblastoma and furthering development in ourpoint-of-care approach withT-cellCAR-based therapies,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology. “ZIOPHARM is assessing several paths for the pivotal trial, including asingle-arm study ofAd-RTS-hIL-12 + veledimex compared to historical controls. With a commercialization path in view, we are evaluating partnership opportunities forAd-RTS-hIL-12 + veledimex to understand the breadth of options available to ZIOPHARM for bringing this important therapeutic candidate to patients.”
“TheIL-12 data from the brain cancer trial firmly establishes that the RheoSwitch Therapeutic System® works as a switch in humans,” added Dr. Cooper. “By combining the most clinically advancednon-viral gene integration platform,Sleeping Beauty, and transcriptional switch system, RheoSwitch, we will use ourpoint-of-care approach to significantly shorten the time to manufacture T cells and to tailor the expression of introduced genes after infusion using veledimex. This will address two major issues withCAR-based therapies, namely the cost of therapy and control of T cells to reduce toxicity.”
Recent Updates
Ad-RTS-hIL-12 + veledimex
Ad-RTS-hIL-12 + veledimex is ZIOPHARM’s gene therapy candidate for the controlled expression ofinterleukin-12(IL-12), a critical protein for stimulating an anti-cancer immune response, using a RheoSwitch Therapeutic System® (RTS®) inducible gene-delivery system, or switch, that enables controlledin vivo expression of therapeutic proteins. ZIOPHARM is currently conducting a multi-center Phase 1 study ofAd-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma multiforme (GBM), an aggressive form of brain cancer.
ZIOPHARM will be presenting updated results from its Phase 1, multicenter, dose-escalation study ofAd-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2017.
“Our initial discussions with regulators have been encouraging, and we look forward to movingAd-RTS-hIL-12 + veledimex into a pivotal study as quickly as possible this year. Details of the pivotal Phase 3 trial will be made available following completion of discussions with regulators and clinical advisors,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM. “We continue to see encouraging outcomes in our Phase 1, multi-center study ofAd-RTS-hIL-12 + veledimex in patients with recurrent high-grade gliomas and plan to share updated results from this study at ASCO.”
The Company also expects to initiate Phase 1 studies ofAd-RTS-hIL-12 + veledimex in pediatric brain cancer, as well as in combination with ananti-PD-1 checkpoint inhibitor in adult glioblastoma, as planned, in the first half of 2017.
Adoptive Cell Therapies
ZIOPHARM is developing chimeric antigen receptor (CAR) T cell (CAR+ T),T-cell receptor (TCR) T cell (TCR+ T), and natural killer (NK) adoptive cell-based therapies. These programs are being advanced in collaboration with Intrexon Corporation, MD Anderson Cancer Center, the National Cancer Institute and Merck Serono, the biopharmaceutical business of Merck KGaA (CAR+T only).
Announced Advancement of Next-GenerationNon-Viral CAR+ T Platform Empowered by Membrane-BoundIL-15 Under RTS® Gene Switch Control.In April 2017, ZIOPHARM and its partners, Intrexon and Merck KGaA, Darmstadt, Germany, announced the advancement of a unique approach to develop therapeutic candidates for two CAR+ T targets expressed on a wide range of tumor types, including hematologic malignancies and solid tumors. The distinctive methodology centers on the proprietary RTS® platform to regulate production of membrane-bound interleukin-15 (mbIL15)co-expressed with CARs andSleeping Beauty, anon-viral genetic modification system to genetically modify clinical-grade T cells. The companies expect to advance this innovative approach towards the clinic in 2018.
TheIL-15 cytokine is increasingly recognized as a key driver of therapeutic effect in CAR+T therapy, including in a recent Journal of Clinical Oncology publication which correlated lymphoma remissions in patients whoseIL-15 levels were elevated after lymphodepleting chemotherapy. Through the RTS® gene switch, the expression of mbIL15 can be regulated to help CARs target cancers in a controlled manner, thus providing a new paradigm inT-cell therapy.
Announced Advances inPoint-of-Care Approach for Rapidly ProducingCAR-Expressing T Cells Utilizing theSleeping BeautySystem.In January 2017, ZIOPHARM announced improved production times utilizing its non-viral platform to engineer T cells in an ongoing Phase 1 study of second-generationSleeping Beauty-modified CD19-specific CAR+ T cells. ZIOPHARM continues to refine itsSleeping Beauty system to further reduce time to manufacture genetically modified T cells. Preclinical studies of third-generationSleeping Beauty-modified CAR+ T cells co-expressing mbIL15 demonstrated reduced time to administration (less than two days) through elimination of the need forin vitroT-cell activation and propagation. Plans to
2
progress thispoint-of-care approach with infusion of CAR+ T cells in less than two days are underway. The combination ofSleeping Beauty and RTS-mbIL15, has the potential to solve the dual problems of cost and toxicities as genetically modified T cells can be rapidly produced for preclinical testing, and the RTS is a clinically validated switch, which may be used with veledimex to controlT-cell persistence via conditional expression of mbIL15. The Company expects to advance towards a Phase 1 study evaluating thepoint-of-care in 2017.
Announced Cooperative Research and Development Agreement (CRADA) With the National Cancer Institute UtilizingSleeping Beauty System to Generate T Cells Targeting Neoantigens. In January 2017, ZIOPHARM and its partner, Intrexon, announced the signing of a CRADA with the National Cancer Institute (NCI) for the development of adoptive cell transfer-based immunotherapies genetically modified using theSleeping Beauty system to express TCRs targeting neoantigens for the treatment of solid tumors. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI’s Center for Cancer Research. The Company anticipates that this program will advance to Phase 1 during the second half of 2017.
Anticipated and Achieved 2017 Milestones
| | • | | Intra-tumoralIL-12 RheoSwitch® programs: |
| | • | | Updated clinical data from Phase 1 ofAd-RTS-hIL-12 + veledimex for recurrent GBM to be presented at ASCO |
| | • | | Initiate pivotal clinical trial for recurrent GBM |
| | • | | Initiate combination study ofAd-RTS-hIL-12 + veledimex with iCPI(anti-PD-1) for recurrent GBM during the first half |
| | • | | Initiate Phase 1 study in the treatment of brain tumors in children during the first half |
| | • | | Continue CD19-specific CAR+ T second-generation clinical study, enrolling patients under shortened manufacturing |
| | • | | Advance CD19 third-generation mbIL15 towards a Phase 1 clinical study evaluatingpoint-of-care |
| | • | | Initiate a CD33-specific CAR+ T clinical study in adults and children for relapsed or refractory acute myeloid leukemia |
| | • | | Advance CAR+T-cell preclinical studies for at least one hematological malignancy under a shortened manufacturing process towardspoint-of-care |
| | • | | Execute CRADA with NCI utilizingSleeping Beauty to generate T cells targeting neoantigens for treatment of patients with solid tumor malignancies |
| | • | | Advance development of process for delivering personalized gene-modifiedT-cell products against neoantigens |
| | • | | Initiate a Phase 1 study ofoff-the-shelf (OTS) NK cells for elderly patients with acute myeloid leukemia not eligible for standard intensive chemotherapy |
| | • | | GvHD (graft-versus-host disease) programs |
| | • | | Advance preclinical studies |
3
First-Quarter 2017 Financial Results
| | • | | Net loss applicable to the common shareholders for the first quarter of 2017 was $19.7 million, or $(0.15) per share, compared to a net loss of $12.0 million, or $(0.09) per share, for the first quarter of 2016. The increase in net loss for the three months ended March 31, 2017 is primarily due to decreased collaboration revenue of $0.4 million, an increase in operating expenses of $1.5 million, an increase in the charge for the change in derivative liabilities of $1.6 million and income attributable to preferred shareholders of $4.2 million. |
| | • | | Research and development expenses were $12.0 million for the first quarter of 2017, compared to $10.2 million for the first quarter of 2016. The increase in research and development expenses for the three months ended March 31, 2017 is primarily due to our gene therapy and cell therapy programs, along with increased headcount. |
| | • | | General and administrative expenses were $3.6 million for the first quarter of 2017, compared to $3.8 million for the first quarter of 2016. The decrease in general and administrative expenses is primarily due to decreased employee-related expenses. |
| | • | | The Company ended the quarter with cash and cash equivalents of approximately $66.4 million, which the Company believes will be sufficient to fund its currently planned activities through the fourth quarter of 2017, including initiating a pivotal trial for Ad-RTS-hIL-12 + veledimex. |
Conference Call and Slide Webcast
ZIOPHARM will host a conference call and webcast slide presentation today, Monday, May 1, 2017, at 4:30 p.m. ET. The call can be accessed by dialing (844)309-0618 (U.S. and Canada) or (661)378-9465 (international). The passcode for the conference call is 8375689. To access the slides and live audio webcast, or the subsequent archived recording, visit the “Investors & Media” section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.
About ZIOPHARM Oncology, Inc. ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company’s immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR+ T) and other adoptive cell-based approaches that usenon-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation’s RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor Statement
This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the Company’s plans and
4
expectations regarding its securities offerings, fundraising activities and financial strategy, the progress, timing and results of preclinical and clinical trials involving the Company’s drug candidates, and the progress of the Company’s research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to finance our operations and business initiatives and obtain funding for such activities, whether chimeric antigen receptor T cell (CAR+ T) approaches,Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the preclinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR+ T) approaches,Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form10-K for the fiscal year ended December 31, 2016 and our Quarterly Report on Form10-Q for the quarter ended March 31, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of ornon-occurrence of any events.
Trademarks
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.
Contact:
Amy Trevvett
Vice President, Corporate Communications
and Investor Relations
617-502-1881
atrevvett@ziopharm.com
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
(tables follow)
5
ZIOPHARM Oncology, Inc.
Statements of Operations
(in thousands except share and per share data)
(unaudited)
| | | | | | | | |
| | | Three Months Ended | |
| | | March 31, | |
| | | 2017 | | | 2016 | |
| | |
Collaboration revenue | | $ | 1,597 | | | $ | 1,969 | |
| | | | | | | | |
| | |
Operating expenses: | | | | | | | | |
| | |
Research and development, including cost of contracts | | | 11,967 | | | | 10,199 | |
| | |
General and administrative | | | 3,595 | | | | 3,810 | |
| | | | | | | | |
| | |
Total operating expenses | | | 15,562 | | | | 14,009 | |
| | | | | | | | |
| | |
Loss from operations | | | (13,965 | ) | | | (12,040 | ) |
| | |
Other income (expense), net | | | 38 | | | | 21 | |
| | |
Change in derivative liabilities | | | (1,560 | ) | | | — | |
| | | | | | | | |
| | |
Net loss | | | (15,487 | ) | | | (12,019 | ) |
| | |
Preferred stock dividends | | | (4,171 | ) | | | — | |
| | | | | | | | |
Net loss applicable to common stockholders | | $ | (19,658 | ) | | $ | (12,019 | ) |
| | | | | | | | |
| | |
Basic and diluted net loss per share | | $ | (0.15 | ) | | $ | (0.09 | ) |
| | | | | | | | |
| | |
Weighted average common shares outstanding used to compute basic and diluted net loss per share | | | 130,696,400 | | | | 130,157,927 | |
| | | | | | | | |
6
ZIOPHARM Oncology, Inc.
Balance Sheet Data
(in thousands)
(unaudited)
| | | | | | | | |
| | | March 31, | | | December 31, | |
| | | 2017 | | | 2016 | |
| | |
Cash and cash equivalents | | | 66,447 | | | | 81,053 | |
Working capital | | | 77,030 | | | | 89,075 | |
Total assets | | | 94,494 | | | | 106,348 | |
Total stockholders’ equity (deficit) | | | (94,903 | ) | | | (77,298 | ) |
7
